Marshall Wace, LLP Mei Pharma, Inc. Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.54 - $2.74 $143,952 - $730,426	-266,579 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.33 - $3.37 $621,129 - $898,371	266,579 New	266,579 $712,000
Q3 2020 Nov 16, 2020	SELL	$2.46 - $4.27 $1.33 Million - $2.31 Million	-541,785 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$1.45 - $4.3 $785,588 - $2.33 Million	541,785 New	541,785 $2.24 Million
Q4 2019 Feb 14, 2020	SELL	$1.65 - $2.48 $29,559 - $44,429	-17,915 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$1.48 - $2.52 $26,514 - $45,145	17,915 New	17,915 $30,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $366M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.